NATIONAL HEALTH (PHARMACEUTICAL BENEFITS) AMENDMENT REGULATIONS 2010 (NO5) (SLI NO 296 OF 2010) - REG 8 Transitional -- listed brand having same drug and manner of administration as listed brand already subject to price disclosure requirements -- first reporting period for brand in third transitional cycle [100%]
(From Commonwealth Numbered Regulations; 1 January 2010; 4 KB)